Bruker Corporation (Nasdaq: BRKR), a provider of high performance scientific instruments and high value analytical and diagnostic solutions, announced on Wednesday that it has successfully acquired Spectral Instruments Imaging LLC (SII), a provider of preclinical in-vivo optical imaging systems. This strategic move enhances the technology and product range of Bruker BioSpin Preclinical Imaging (PCI) division, strengthening its offerings for disease research.
Founded in 2009 in Tucson, Spectral Instruments Imaging is a pioneer in co-registered bioluminescence (BLI), fluorescence (FLI) and X-ray preclinical imaging. SII systems, including the flagship Lago X and high-efficiency AMI HTX, feature advanced optics, patented illumination, -90o C air-cooled high sensitivity cameras and absolute calibration for quantifiable imaging, ensuring flexibility and ease of use. The SII Aura software streamlines workflows for enhanced productivity.
Keith Copeland, CEO of SII, highlighted that the acquisition marks a significant milestone, anticipating that customers will benefit from a broader range of preclinical imaging modalities to understand biological disease processes comprehensively in vivo.
While financial details of the acquisition remain undisclosed, Spectral Instruments Imaging reported revenues exceeding USD10m and profitability in 2023. Bruker's acquisition aligns with its commitment to empowering scientists through high-performance instruments and analytical solutions, fostering innovation and success in various life science disciplines, including preclinical imaging, clinical phenomics research, proteomics and multiomics, among others.
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma